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Abstract: This manuscript describes the use of a novel biochip platform for the rapid 
analysis/identification of nucleic acids, including DNA and microRNAs, with very high 
specificity. This approach combines a unique dynamic chemistry approach for nucleic acid 
testing and analysis developed by DestiNA Genomics with the STMicroelectronics  
In-Check platform, which comprises two microfluidic optimized and independent PCR 
reaction chambers, and a sequential microarray area for nucleic acid capture and 
identification by fluorescence. With its compact bench-top “footprint” requiring only a 
single technician to operate, the biochip system promises to transform and expand routine 
clinical diagnostic testing and screening for genetic diseases, cancers, drug toxicology and 
heart disease, as well as employment in the emerging companion diagnostics market. 
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1. Introduction 
The development of rapid diagnostic device platforms is one of the major scientific aims in the 
world of life-science research, drug discovery, medical diagnostics and biotechnology [1–7]. Several 
point-of-care (POC) diagnostic platforms have been launched in the past few years with some 
approved by the Food and Drug Administration (FDA) for in vitro diagnostic (IVD) applications [8–10]. 
Emerging nucleic acid test (NAT) technologies have allowed the development of applications for 
genotyping [single nucleotide polymorphisms (SNPs) and indel identification], epigenetic studies, 
array comparative genome hybridisation (aCGH), pre-natal screening, and microRNAs (miRNAs) 
profiling to name just a few, providing substantial future growth opportunities for LoC devices [11–18]. 
LoC approaches could overcome the technical limitations of nucleic acid mass screening by providing 
rapid, cheap and multiplexed assays [13,15]. 
Among the advanced biochip-based technologies, STMicroelectronics has developed a disposable 
silicon-based micro electro mechanical system (MEMS) LoC device as a part of their “In-Check” 
platform [19–21]. This platform combines all the functions needed to identify given oligonucleotide 
sequences in a sample and includes microfluidic handling, a miniaturized PCR reactorand a nucleic 
acid microarray detection module (Figure 1). 
The In-Check platform has already been used successfully to amplify human genome sequences and 
detect human genome mutations, such as the gene associated with β-thalassemia as well as the 
detection of viral infectious diseases with full integration of the PCR amplification with subsequent 
microarray detection [22–24]. 
Previously, the chemical-based approach for nucleic acid testing (Chem-NAT) commercialised by 
DestiNA Genomics had been validated by genotyping, with 100% read accuracy, using DNA from 
mouth swabs from Cystic Fibrosis (CF) patients and mass spectrometry (MALDI-ToF) for analysis [25]. 
Briefly, DestiNA core technology takes advantage of dynamic chemistry for nucleic acid sequence 
specific recognition using aldehyde-modified natural nucleobases (so called SMART nucleobases), 
and probes based on peptide nucleic acid (PNA), containing an “abasic” position (DestiNA probes) 
which can be made complementary to any target nucleic acid sequence (Figure 2(A)) [26]. 
A major feature of Chem-NAT is that false positives are difficult if not impossible to create as 
nucleobase incorporation can only occur in the presence of target templating nucleic acid strands 
Figure 2(A). 
While mass spectrometry allows single base discrimination and multiplexing capabilities due to 
molecular weight differences between SMART nucleobases, fluorescence based assays require the 
DestiNA SMART nucleobases to be fluorescently-labelled and the DestiNA probes to be modified to 
allow their covalent immobilisation on surfaces Figure 2(B,C). 
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Figure 1. The main components of In-Check platform: (A) The Lab-on-Chip core device 
amplifies clinically relevant DNA samples by Polymerase Chain Reaction (PCR) and has 
an integrated custom low-density microarray (showed by the white arrow). (B) In-Check 
platform instruments. The Lab-on-Chip interfaces to the Temperature Control System 
(TCS) that actuates, monitors, and controls the parameters of the reaction. The TCS unit 
comprises five control modules with independent thermal protocols and random access 
capability. Optical signal acquisition is performed on a dedicated portable reader and 
processed by ST's specialized bioinformatics software. The software package allows users 
to easily monitor and control reaction processes, analyse the results and automatically 
generate diagnostic reports. 
 
Multiplexing can be achieved by printing probes at defined XY coordinates and by incorporation of 
the correct fluorescently-labelled SMART nucleobase into the chemical pocket following duplex 
hybridisation. Such an application allows the use of label-free nucleic acids. 
Herein, a proof-of-concept study which integrates DestiNA Genomics Chem-NAT with 
STMicroelectronics In-Check LoC platform is described, delivering a novel biochip platform for the 
rapid detection of nucleic acids with high sensitivity and specificity. 
The novel biochip platform was evaluated and validated for detection of synthetic small RNAs 
(sRNAs) based on microRNA-122 (miRNA122) and mengo virus RNA (MGV). This biological model 
represents the first steps in the development of a novel suite of assays for the medical diagnostic field. 
Integration of DestiNA technology with the STMicroelectronics In-Check LoC creates a highly 
innovative product with a true diagnostic potential and utility, for rapid detection of nucleic acids with 
benefits in terms of result consistency, time, cost, and ease of use. 
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Figure 2. (A) The steps involved in DestiNA Genomics chemical-based approach for 
nucleic acid testing (Chem-NAT). (Copyright Wiley-VCH Verlag GmbH & Co. KGaA, 
Reproduced with permission) [26]. DestiNA probe with the target sequence to be detected 
creates a molecular pocket (step 1) that allows the speciﬁc incorporation of a DestiNA 
SMART nucleobase (step 2) which is then chemically locked into position (step 3). 
SMART nucleobase incorporation can be directly detected by Mass Spectrometry.  
(B) Structure of the fluorescein labelled aldehyde Cytosine (FITC-CCHO) for detection 
using ﬂuorescence reporter system. (C) Structures of a DestiNA probe containing a  
N-terminated amino peg-ylated spacer for being covalently immobilised onto surfaces. 
 
2. Experimental Procedure and Methods 
2.1. General 
STMicroelectronics In-Check LoC platforms were fabricated as described previously [19]. 
Commercially available reagents and buffer for the functionalization of the LoC surfaces were used 
without further purification. Hydrogen peroxide (29%), ammonium hydroxide (25%), hydrochloridric 
acid (37%) and methanol were purchased from Sigma Aldrich (Poole,UK) and were used as received. 
Spot buffer (Nexterion Spot) and hybridisation solution (Nexterion Hyb) were purchased from 
SCHOTT and were used as received. All synthetic RNA oligomers were purchased in desalted form 
from Microsynth AG (Balgach, Switzerland). 
2.2. Instrumentations 
A microdrop inject printer equipped with a micro-pipette (AD-K-501 70 μm diameter nozzle) 
(Microdrop Technologies GmbH, Muehlenweg, Norderstedt, Germany) and a BioAnalyzer 4F/4S 
equipped with a light scanner (LaVision BioTech GmbH, Bielefeld, Germany) were used. DestiNA 
probe aqueous solutions concentrations were determined using an Agilent 8453 spectrophotometer. 
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Hybridisation was carried out on a Q-Hyb10 Hybridisation Oven Incubation System Deltaspin (Quanta 
Biotech Ltd., Surrey, UK). 
2.3. Probe Synthesis and Puriﬁcation 
DestiNA probes terminate with an amino PEG group and were prepared by solid-phase synthesis 
(SPS) using Fmoc/Bhoc protected monomers as described previously [25] and were characterized by 
MALDI-TOF mass spectrometry (see Figures S1 and S2 in the Supplementary Information). 
2.4. Synthesis of FITC Labelled Aldehyde Cytosine 
Aldehyde-modified cytosine, tagged with a fluorescein molecule was prepared following the 
synthetic route described elsewhere [27] and characterized by MALDI-TOF mass spectrometry (see 
Figure S3 in the Supporting Information). 
2.5. Probes Immobilization 
Attachment of DestiNA probes was carried out according to manufacturer’s protocols (SCHOTT). 
Brieﬂy, amino peg-ylated spacer probes were dissolved in 1X spotting solution to give 100 µM 
solutions. The solution was spotted onto the epoxysilane-functionalised LoC, followed by incubation 
under humidity for 30 min in a hybridisation chamber box (Genetix). Thereafter, the LoCs were 
washed for 5 min in 0.1% Triton X-100, 2 × 2 min in 1 mM HCl, 10 min in 100 mM KCl and 1 min in 
deionized water. After washing, the LoCs were blocked in 150 mM phosphate buffer containing  
50 mM dimethylamine, pH 9, for 15 min at 50 °C with stirring. The LoCs were washed for one min 
with deionized water, dried in an oil-free nitrogen stream and stored at room temperature until use. 
2.6. Validation of DestiNA Probes Immobilization 
Features on the LoCs were hybridized with complementary labelled synthetic sRNAs (see  
Table S1, target 1 and 2, in the Supporting Information). In short, in a 0.2 mL Eppendorf, 10 µL of  
100 µM of labelled synthetic sRNAs were dissolved in 20 µL of diH2O. Samples were mixed with  
30 µL of hybridisdation buffer and in accordance with the guidelines provided by STMicrelectronics, 
this solution was loaded into LoCs (through to the two inlets to reach the microarray area). The arrays 
were covered with two accessories in plastic (clamps) for array sealing and inserted into the 
Hybridisation Oven for hybridisation. Hybridisation was standardised by treatment at 50 °C for 2 h. 
Thereafter, clamps were removed, and the LoCs were washed for 10 min each in 2 × SSC + 0.1% 
SDS, 2 × SSC and then 0.2 × SSC (all wash steps were performed at room temperature). LoCs were 
dried using an oil-free nitrogen stream and scanned using a 100 ms exposure time using emission and 
detection filters appropriate for FITC. 
2.7. DestiNA Reaction on LoC 
A 0.2 mL Eppendorf containing 5 µL of a 100 µM unlabelled miRNA122 oligomer aqueous 
solution (see Table S1, target 3 in the Supporting Information) was placed in a heater (Techne TC-312 
Thermocycler) at 95 °C for 5 min, then cooled to 40 °C before being combined with 10 µL of 
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NaBH3CN (1 M) and 15 µL of FITC labelled aldehyde cytosine (FITC-CCHO) (100 µM in 0.5% 
DMSO aqueous solution). Samples were mixed with 30 µL of hybridisation buffer (final volume  
60 µL) and loaded onto the LoC as described above. The arrays were covered with the two clamps and 
placed into the hybridisation oven at 50 °C for 2 h. After the reaction the LoCs were washed, dried and 
scanned as described above. 
3. Results and Discussion 
In a first phase of this feasibility study, a protocol to print DestiNA probes onto LoC using an inkjet 
printer was developed. Once the printing and blocking conditions were optimised, a second phase was 
carried out in order to check if DestiNA probes, covalently immobilized on the LoC, were able to form 
duplexes with complementary synthetic sRNA oligomers. In a final stage dynamic incorporation of 
FITC-CCHO was tested to determine if high specificity was achieved on the novel biochip platform. 
3.1. DestiNA Probes for In-Check  
In this study two different RNA strands mimicking natural sRNAs were used to validate the 
methodologies. The two objects of this study were related to miRNA122 and MGV. miRNA122 is a 
22 nucleotide long single strand RNA found in high concentrations in human plasma of patients who 
have overdosed on paracetamol, becoming a prospective biomarker of liver damage [28]. MGV can be 
passed to humans through food intake, mainly in shellfish and analysis in the food chain is important 
to avoid major outbreaks of hepatitis A [29]. The MGV transcript is over 3,000 Kb long and the target 
region selected was chosen based on recommendation of the European Committee for Standardisation 
(CEN/TC 275/WG6/TAG4-viruses in foods).  
To investigate and discriminate between the chosen targets, two different DestiNA probes, one to 
clamp the mature miRNA122 sequence and the one targeting MGV genomic RNA, were designed and 
synthesised. The design aligned the N-terminal end of the probes with the 3' end of their target having 
the “blank” position lined up opposite to a guanidine residue under interrogation, as shown in Figure 3. 
Figure 3. miRNA122 and MGV were interrogated using two different DestiNA probes  
(1 and 2) 18 and 20 mers respectively. Incorporation of FITC-CCHO provides proof-reading, 
indicating the presence of the complementary oligomers. Only with perfect complementarity 
the FITC-CCHO SMART nucleobase will be incorporated. Probe design was carried out 
using publicly available database (miRBase Accession Number: MIMAT0000421). MGV 
was designed using the real-time probe Mengo147 previously published [29]. “*” The 
single-stranded DNA probe Mengo147 was an identical version of the mengo virus 
genomic RNA except that “T” bases were replaced with “U” bases. 
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DestiNA probes were reacted chemoselectivity with the epoxy groups that coat the silicon-based 
microarray surface of the In-Check LoC. 
Figure 4 shows an amino-modified DestiNA probe reacting with the epoxysilane surface of the  
LoC (a reaction that does not need additional baking or UV cross-linking steps). Molecular spacers  
(PEG group) between the probes and the LoC epoxy groups facilitate interactions between the printed 
DestiNA probes and their target binding partners in solution. 
Figure 4. Modified DestiNA probes immobilization. DestiNA probes were covalently 
attached through an epoxide ring-opening reaction via their primary amines. 
 
3.2. Printing and Blocking Optimization 
An important stage in the construction of the novel LoCs was defining the microarray probe layout. 
The two test probes were printed onto two symmetrical portions of the array (pattern 1 and 2) and 
arranged in 15 rows and six columns (90 features in total). Taking into consideration the size of the 
microarray of 3.7 mm × 1.45 mm, it was decided to create a spot pitch of 250 µm Figure 5(A). Corner 
control FITC-labelled DNA oligomers (see Table S1 in the Supporting Information) were printed to 
identify array orientation. Empty positions to evaluate background noise were provided. Overall,  
32 positions were allocated to the control probes and 64 to the specific probes Figure 5(A).  
Printing was performed using a proprietary non-contact inkjet printing process in which DestiNA 
probes were deposited uniformly onto the LoC microarray area. The precise inkjet process enabled the 
delivery of extremely small, accurate volumes (picoliters) of the chemicals Figure 5(B). 
Efficient blocking of reactive surface groups after arraying was critical for a reduced fluorescence 
background. The LoC was blocked with a 150 mM phosphate buffer containing 50 mM dimethylamine. 
The tertiary amines engendered prevented reactions with the aldehyde groups of the FITC-CCHO  
Figure 5(C). Standard SCHOTT blocking buffer (containing ethanolamine) blocking approach were 
excluded as this would give rise to secondary amines on the surface which could react with the 
aldehyde groups of the fluorescently-labelled SMART nucleobase. 
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Figure 5. (A) Graphic layout of the microarray. (B) Printing station with a microdrop 
printer GmbH (Norderstedt, Germany) containing a micro-pipette with a 70 µm diameter 
nozzle. (C) Efficient blocking using 150 mM phosphate buffer containing 50 mM 
dimethylamine. Red square shows the tertiary amines formed. 
 
3.3. Printing Validation with Synthetic Oligonucleotides 
Following printing of the probes on the LoC microarray area, the performance of the DestiNA 
probes was initially checked by hybridizing complementary fluorescently-labelled sRNA oligomers 
(see Table S1, target 1 and 2 in the Supporting Information). Figure 6 shows fluorescence scanning 
images of those areas, clearly demonstrating the ability of the immobilised DestiNA probes to 
recognise and form duplexes with complementary nucleic acid strands. 
Good printing performance and excellent spot morphology for both probe 1 and 2 was observed. 
Pattern 1 (left image) shows where the oligo miRNA122 FITC plus complementary DestiNA probe 1, 
attached to the LoC surface, has correctly hybridised and fluoresces. Pattern 2 (left image) shows no 
fluorescence, as the oligo miRNA122 FITC had no complementarity to DestiNA probe 2 and, was 
washed away. Additionally, Pattern 2 (right image) shows where the oligo MGV FITC plus 
complementary DestiNA probe 2 has correctly hybridised and fluoresces, while Pattern 1 (right image) 
shows no fluorescence, as the oligo MGV had no complementarity to DestiNA probes 1. 
3.4. DestiNA Reaction on In-Check LoC Platform 
After optimising the printing, blocking conditions and validating the capability of DestiNA probes 
to efficiently hybridise only with complementary sequence sRNA oligomers, the ability to achieve a 
DestiNA Chem-NAT dynamic chemistry protocol on the LoC devices was explored. Unlabelled 
miRNA122 (see Table S1, target 3 in the Supporting Information) was used as template strand and 
FITC-CCHO nucleobase was used with LoCs previously arrayed with DestiNA probes (Figure 5(A)). The 
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resulting LoC scanning (Figure 7) showed the ability of the DestiNA technology to identify miRNA122 
oligomer on In-Check, using a highly selective incorporation of the fluorescently-labelled cytosine. 
Figure 6. LoCs scanned after the hybridisation of DestiNA probes with either synthetic 
miRNA122-FITC (left) or MGV-FITC (right). LoCs were scanned using a 200 ms 
exposure time using emission and detection filters appropriate for FITC.  
 
Figure 7. LoC scanned after DestiNA reaction with FITC-CCHO. Red square (pattern 1) 
shows where the oligo miRNA122 plus complementary DestiNA probe 1 attached to the 
array has correctly hybridised and fluorescence due to FITC-CCHO incorporation (showed 
by black arrow). On the other hand, red square (pattern 2) does not show fluorescence  
due to an absence of hybridisation between oligo miRNA122 plus DestiNA probe 2  
(FITC-CCHO incorporation not take place). 
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Background was at a very low level, demonstrating excellent blocking and the benefit of the proof 
reading step using the DestiNA SMART base protocol. 
Selective incorporation of FITC-CCHO into the PNA/RNA hybrid through dynamic chemical 
reactions can take place ONLY when miRNA122 forms a perfect duplex with the designed DestiNA 
probes (pattern 1). Pattern 2 shows no fluorescence because non-complementary (miRNA122) has not 
been hybridised with the PNA probe 2. This demonstrated the selective incorporation of the “correct” 
base when the target nucleic acid forms a perfect duplex. The result confirms that the DestiNA 
fluorescence detection approach to nucleic acid discrimination reported here could be ported into the 
LoC platform, facilitating the analysis of label-free nucleic acid. The result further indicates that the 
approach used with miRNA122 herein could be extended to more generic, direct nucleic acid analysis 
such as allele-discrimination. 
4. Conclusions 
In this manuscript we have given an overview of a “Proof of Concept” study for testing the 
integration of DestiNA Genomics and STMicroelectronics technologies. All the key proof of concept 
objectives were achieved, including effective DestiNA probe printing and DestiNA reactions, 
demonstrating successful translation of DestiNA reagents onto the In Check LoC platform. This study 
represents a first step in merging the two technologies to create a suite of novel medical diagnostic 
assays capable of delivering a novel biochip platform for the rapid detection of nucleic acids with high 
sensitivity and specificity.By combining the novel chemical-based methods with the Lab-on-Chip 
platform, clinically valuable innovation is achieved through: 
1. The unique high affinity and selective hybridisation between DestiNA probes and target DNA or 
RNA, superior to standard DNA/DNA or DNA/RNA hybridisations. 
2. The innovative DestiNA probes, that contain a “blank”/nucleobase free position within the 
probe, enable a unique proof-reading step to occur. A rapid and selective incorporation of 
complementary fluorescently labelled SMART nucleobase into the PNA/RNA hybrid can ONLY 
occur if the target nucleic acid forms a perfect duplex with the designed DestiNA probe.  
3. Flexibility to design “personalized” and low cost multiplex assays for target detection in 
individuals able to be undertaken by laboratory technicians. 
The integration and combination of DestiNA Genomics and STMicroelectronics technologies are 
very promising and potentially suitable for developing a highly innovative next generation system 
capable of true diagnostic value and utility for the rapid detection of nucleic acids. Benefits for health 
care providers will be cost benefits in term of reliability, time, and ease of use. 
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